Global Kidney Disease Market

Kidney Disease Comprehensive Study by Type (Chronic Kidney Disease, Acute Kidney Disease), Treatment (Dialysis, Medication, Kidney Transplantation), End-users (Dialysis Centers, Hospital & Clinics, Research and Academic Institutes), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others) Players and Region - Global Market Outlook to 2030

Kidney Disease Market by XX Submarkets | Forecast Years 2024-2030  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About Kidney Disease
Previous hospital-based studies in Ethiopia showed a CKD prevalence of 18.2% and 23.8% and using modification of diet in renal diseases (MDRD) and Cockroft-Gualt (CG) equations, respectively, in patients with diabetes. Kidney disease means kidneys are damaged and can't filter as well. Kidney disease affected approximately 26 million American adults. Kidney damage may be caused by diabetes, high blood pressure, and various other chronic (long-term) conditions. The most common form of kidney disease is chronic kidney disease. It is a long term condition that doesn't improve over time.

AttributesDetails
Study Period2018-2030
Base Year2023
UnitValue (USD Million)


The companies are exploring the market by adopting expansions, investments, new service launches and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions across the globe to gain a competitive advantage through combined collaborations. Analyst at AMA Research estimates that Global Players will contribute the maximum growth to Global Kidney Disease market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

Taro Pharmaceutical Industries Ltd. (United States), Otsuka Pharmaceutical Co., Ltd. (Japan), Novartis International AG (Switzerland), Merck & Co. Inc. (United States), Sanofi S.A. (France), Amgen Inc. (United States), AstraZeneca plc (United Kingdom), Teva Pharmaceutical Industries Ltd. (Israel) and Bristol-Myers Squibb Company (United States) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research coverage are Fresenius Kabi AG (Germany) and Pfizer Inc. (United States).

Segmentation Overview
AMA Research has segmented the market of Global Kidney Disease market by Type (Chronic Kidney Disease and Acute Kidney Disease) and Region.



On the basis of geography, the market of Kidney Disease has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Treatment, the sub-segment i.e. Dialysis will boost the Kidney Disease market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by End-users, the sub-segment i.e. Dialysis Centers will boost the Kidney Disease market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Distribution Channel, the sub-segment i.e. Hospital Pharmacy will boost the Kidney Disease market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Influencing Trend:
Technological Advancements in Medical Science and Increased Research and Development Activities

Market Growth Drivers:
Increased Population Suffering from Kidney Disease and Increased Prevalence of Diabetes and Hypertension

Challenges:
Stringent Government Rules and Regulations

Restraints:
Rising Healthcare Cost

Opportunities:
Growth in the Geriatric Population and Growing Healthcare Industry Worldwide

Market Leaders and their expansionary development strategies
In August 2023, Signify Health, a CVS Health company, announced the addition of a comprehensive in-home kidney health evaluation to its Diagnostic and Preventive Services offering. The new screenings expand Signify Health's suite of services designed to support the early detection, diagnosis, and management of some of the leading causes of morbidity and mortality among people covered under Medicare Advantage.
In October 2022, The National Kidney Foundation (NKF) launched a new animated video series aimed at educating people on their chronic kidney disease (CKD) risk. “Kidney Numbers and the CKD Heat Map” is a new initiative that conveys complex health information while targeting patients with varying levels of health literacy. The “Kidney Numbers and the CKD Heat Map” initiative is supported by Bayer.


Key Target Audience
Kidney Disease Treatment Providers, Emerging Professionals, Research Professionals and End-users

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Type
  • Chronic Kidney Disease
  • Acute Kidney Disease
By Treatment
  • Dialysis
  • Medication
  • Kidney Transplantation

By End-users
  • Dialysis Centers
  • Hospital & Clinics
  • Research and Academic Institutes

By Distribution Channel
  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increased Population Suffering from Kidney Disease
      • 3.2.2. Increased Prevalence of Diabetes and Hypertension
    • 3.3. Market Challenges
      • 3.3.1. Stringent Government Rules and Regulations
    • 3.4. Market Trends
      • 3.4.1. Technological Advancements in Medical Science
      • 3.4.2. Increased Research and Development Activities
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Kidney Disease, by Type, Treatment, End-users, Distribution Channel and Region (value) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Kidney Disease (Value)
      • 5.2.1. Global Kidney Disease by: Type (Value)
        • 5.2.1.1. Chronic Kidney Disease
        • 5.2.1.2. Acute Kidney Disease
      • 5.2.2. Global Kidney Disease by: Treatment (Value)
        • 5.2.2.1. Dialysis
        • 5.2.2.2. Medication
        • 5.2.2.3. Kidney Transplantation
      • 5.2.3. Global Kidney Disease by: End-users (Value)
        • 5.2.3.1. Dialysis Centers
        • 5.2.3.2. Hospital & Clinics
        • 5.2.3.3. Research and Academic Institutes
      • 5.2.4. Global Kidney Disease by: Distribution Channel (Value)
        • 5.2.4.1. Hospital Pharmacy
        • 5.2.4.2. Retail Pharmacy
        • 5.2.4.3. Online Pharmacy
        • 5.2.4.4. Others
      • 5.2.5. Global Kidney Disease Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
  • 6. Kidney Disease: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Taro Pharmaceutical Industries Ltd. (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Otsuka Pharmaceutical Co., Ltd. (Japan)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Novartis International AG (Switzerland)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Merck & Co. Inc. (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Sanofi S.A. (France)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Amgen Inc. (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. AstraZeneca plc (United Kingdom)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Teva Pharmaceutical Industries Ltd. (Israel)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Bristol-Myers Squibb Company (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
  • 7. Global Kidney Disease Sale, by Type, Treatment, End-users, Distribution Channel and Region (value) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Kidney Disease (Value)
      • 7.2.1. Global Kidney Disease by: Type (Value)
        • 7.2.1.1. Chronic Kidney Disease
        • 7.2.1.2. Acute Kidney Disease
      • 7.2.2. Global Kidney Disease by: Treatment (Value)
        • 7.2.2.1. Dialysis
        • 7.2.2.2. Medication
        • 7.2.2.3. Kidney Transplantation
      • 7.2.3. Global Kidney Disease by: End-users (Value)
        • 7.2.3.1. Dialysis Centers
        • 7.2.3.2. Hospital & Clinics
        • 7.2.3.3. Research and Academic Institutes
      • 7.2.4. Global Kidney Disease by: Distribution Channel (Value)
        • 7.2.4.1. Hospital Pharmacy
        • 7.2.4.2. Retail Pharmacy
        • 7.2.4.3. Online Pharmacy
        • 7.2.4.4. Others
      • 7.2.5. Global Kidney Disease Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Kidney Disease: by Type(USD Million)
  • Table 2. Kidney Disease Chronic Kidney Disease , by Region USD Million (2018-2023)
  • Table 3. Kidney Disease Acute Kidney Disease , by Region USD Million (2018-2023)
  • Table 4. Kidney Disease: by Treatment(USD Million)
  • Table 5. Kidney Disease Dialysis , by Region USD Million (2018-2023)
  • Table 6. Kidney Disease Medication , by Region USD Million (2018-2023)
  • Table 7. Kidney Disease Kidney Transplantation , by Region USD Million (2018-2023)
  • Table 8. Kidney Disease: by End-users(USD Million)
  • Table 9. Kidney Disease Dialysis Centers , by Region USD Million (2018-2023)
  • Table 10. Kidney Disease Hospital & Clinics , by Region USD Million (2018-2023)
  • Table 11. Kidney Disease Research and Academic Institutes , by Region USD Million (2018-2023)
  • Table 12. Kidney Disease: by Distribution Channel(USD Million)
  • Table 13. Kidney Disease Hospital Pharmacy , by Region USD Million (2018-2023)
  • Table 14. Kidney Disease Retail Pharmacy , by Region USD Million (2018-2023)
  • Table 15. Kidney Disease Online Pharmacy , by Region USD Million (2018-2023)
  • Table 16. Kidney Disease Others , by Region USD Million (2018-2023)
  • Table 17. South America Kidney Disease, by Country USD Million (2018-2023)
  • Table 18. South America Kidney Disease, by Type USD Million (2018-2023)
  • Table 19. South America Kidney Disease, by Treatment USD Million (2018-2023)
  • Table 20. South America Kidney Disease, by End-users USD Million (2018-2023)
  • Table 21. South America Kidney Disease, by Distribution Channel USD Million (2018-2023)
  • Table 22. Brazil Kidney Disease, by Type USD Million (2018-2023)
  • Table 23. Brazil Kidney Disease, by Treatment USD Million (2018-2023)
  • Table 24. Brazil Kidney Disease, by End-users USD Million (2018-2023)
  • Table 25. Brazil Kidney Disease, by Distribution Channel USD Million (2018-2023)
  • Table 26. Argentina Kidney Disease, by Type USD Million (2018-2023)
  • Table 27. Argentina Kidney Disease, by Treatment USD Million (2018-2023)
  • Table 28. Argentina Kidney Disease, by End-users USD Million (2018-2023)
  • Table 29. Argentina Kidney Disease, by Distribution Channel USD Million (2018-2023)
  • Table 30. Rest of South America Kidney Disease, by Type USD Million (2018-2023)
  • Table 31. Rest of South America Kidney Disease, by Treatment USD Million (2018-2023)
  • Table 32. Rest of South America Kidney Disease, by End-users USD Million (2018-2023)
  • Table 33. Rest of South America Kidney Disease, by Distribution Channel USD Million (2018-2023)
  • Table 34. Asia Pacific Kidney Disease, by Country USD Million (2018-2023)
  • Table 35. Asia Pacific Kidney Disease, by Type USD Million (2018-2023)
  • Table 36. Asia Pacific Kidney Disease, by Treatment USD Million (2018-2023)
  • Table 37. Asia Pacific Kidney Disease, by End-users USD Million (2018-2023)
  • Table 38. Asia Pacific Kidney Disease, by Distribution Channel USD Million (2018-2023)
  • Table 39. China Kidney Disease, by Type USD Million (2018-2023)
  • Table 40. China Kidney Disease, by Treatment USD Million (2018-2023)
  • Table 41. China Kidney Disease, by End-users USD Million (2018-2023)
  • Table 42. China Kidney Disease, by Distribution Channel USD Million (2018-2023)
  • Table 43. Japan Kidney Disease, by Type USD Million (2018-2023)
  • Table 44. Japan Kidney Disease, by Treatment USD Million (2018-2023)
  • Table 45. Japan Kidney Disease, by End-users USD Million (2018-2023)
  • Table 46. Japan Kidney Disease, by Distribution Channel USD Million (2018-2023)
  • Table 47. India Kidney Disease, by Type USD Million (2018-2023)
  • Table 48. India Kidney Disease, by Treatment USD Million (2018-2023)
  • Table 49. India Kidney Disease, by End-users USD Million (2018-2023)
  • Table 50. India Kidney Disease, by Distribution Channel USD Million (2018-2023)
  • Table 51. South Korea Kidney Disease, by Type USD Million (2018-2023)
  • Table 52. South Korea Kidney Disease, by Treatment USD Million (2018-2023)
  • Table 53. South Korea Kidney Disease, by End-users USD Million (2018-2023)
  • Table 54. South Korea Kidney Disease, by Distribution Channel USD Million (2018-2023)
  • Table 55. Taiwan Kidney Disease, by Type USD Million (2018-2023)
  • Table 56. Taiwan Kidney Disease, by Treatment USD Million (2018-2023)
  • Table 57. Taiwan Kidney Disease, by End-users USD Million (2018-2023)
  • Table 58. Taiwan Kidney Disease, by Distribution Channel USD Million (2018-2023)
  • Table 59. Australia Kidney Disease, by Type USD Million (2018-2023)
  • Table 60. Australia Kidney Disease, by Treatment USD Million (2018-2023)
  • Table 61. Australia Kidney Disease, by End-users USD Million (2018-2023)
  • Table 62. Australia Kidney Disease, by Distribution Channel USD Million (2018-2023)
  • Table 63. Rest of Asia-Pacific Kidney Disease, by Type USD Million (2018-2023)
  • Table 64. Rest of Asia-Pacific Kidney Disease, by Treatment USD Million (2018-2023)
  • Table 65. Rest of Asia-Pacific Kidney Disease, by End-users USD Million (2018-2023)
  • Table 66. Rest of Asia-Pacific Kidney Disease, by Distribution Channel USD Million (2018-2023)
  • Table 67. Europe Kidney Disease, by Country USD Million (2018-2023)
  • Table 68. Europe Kidney Disease, by Type USD Million (2018-2023)
  • Table 69. Europe Kidney Disease, by Treatment USD Million (2018-2023)
  • Table 70. Europe Kidney Disease, by End-users USD Million (2018-2023)
  • Table 71. Europe Kidney Disease, by Distribution Channel USD Million (2018-2023)
  • Table 72. Germany Kidney Disease, by Type USD Million (2018-2023)
  • Table 73. Germany Kidney Disease, by Treatment USD Million (2018-2023)
  • Table 74. Germany Kidney Disease, by End-users USD Million (2018-2023)
  • Table 75. Germany Kidney Disease, by Distribution Channel USD Million (2018-2023)
  • Table 76. France Kidney Disease, by Type USD Million (2018-2023)
  • Table 77. France Kidney Disease, by Treatment USD Million (2018-2023)
  • Table 78. France Kidney Disease, by End-users USD Million (2018-2023)
  • Table 79. France Kidney Disease, by Distribution Channel USD Million (2018-2023)
  • Table 80. Italy Kidney Disease, by Type USD Million (2018-2023)
  • Table 81. Italy Kidney Disease, by Treatment USD Million (2018-2023)
  • Table 82. Italy Kidney Disease, by End-users USD Million (2018-2023)
  • Table 83. Italy Kidney Disease, by Distribution Channel USD Million (2018-2023)
  • Table 84. United Kingdom Kidney Disease, by Type USD Million (2018-2023)
  • Table 85. United Kingdom Kidney Disease, by Treatment USD Million (2018-2023)
  • Table 86. United Kingdom Kidney Disease, by End-users USD Million (2018-2023)
  • Table 87. United Kingdom Kidney Disease, by Distribution Channel USD Million (2018-2023)
  • Table 88. Netherlands Kidney Disease, by Type USD Million (2018-2023)
  • Table 89. Netherlands Kidney Disease, by Treatment USD Million (2018-2023)
  • Table 90. Netherlands Kidney Disease, by End-users USD Million (2018-2023)
  • Table 91. Netherlands Kidney Disease, by Distribution Channel USD Million (2018-2023)
  • Table 92. Rest of Europe Kidney Disease, by Type USD Million (2018-2023)
  • Table 93. Rest of Europe Kidney Disease, by Treatment USD Million (2018-2023)
  • Table 94. Rest of Europe Kidney Disease, by End-users USD Million (2018-2023)
  • Table 95. Rest of Europe Kidney Disease, by Distribution Channel USD Million (2018-2023)
  • Table 96. MEA Kidney Disease, by Country USD Million (2018-2023)
  • Table 97. MEA Kidney Disease, by Type USD Million (2018-2023)
  • Table 98. MEA Kidney Disease, by Treatment USD Million (2018-2023)
  • Table 99. MEA Kidney Disease, by End-users USD Million (2018-2023)
  • Table 100. MEA Kidney Disease, by Distribution Channel USD Million (2018-2023)
  • Table 101. Middle East Kidney Disease, by Type USD Million (2018-2023)
  • Table 102. Middle East Kidney Disease, by Treatment USD Million (2018-2023)
  • Table 103. Middle East Kidney Disease, by End-users USD Million (2018-2023)
  • Table 104. Middle East Kidney Disease, by Distribution Channel USD Million (2018-2023)
  • Table 105. Africa Kidney Disease, by Type USD Million (2018-2023)
  • Table 106. Africa Kidney Disease, by Treatment USD Million (2018-2023)
  • Table 107. Africa Kidney Disease, by End-users USD Million (2018-2023)
  • Table 108. Africa Kidney Disease, by Distribution Channel USD Million (2018-2023)
  • Table 109. North America Kidney Disease, by Country USD Million (2018-2023)
  • Table 110. North America Kidney Disease, by Type USD Million (2018-2023)
  • Table 111. North America Kidney Disease, by Treatment USD Million (2018-2023)
  • Table 112. North America Kidney Disease, by End-users USD Million (2018-2023)
  • Table 113. North America Kidney Disease, by Distribution Channel USD Million (2018-2023)
  • Table 114. United States Kidney Disease, by Type USD Million (2018-2023)
  • Table 115. United States Kidney Disease, by Treatment USD Million (2018-2023)
  • Table 116. United States Kidney Disease, by End-users USD Million (2018-2023)
  • Table 117. United States Kidney Disease, by Distribution Channel USD Million (2018-2023)
  • Table 118. Canada Kidney Disease, by Type USD Million (2018-2023)
  • Table 119. Canada Kidney Disease, by Treatment USD Million (2018-2023)
  • Table 120. Canada Kidney Disease, by End-users USD Million (2018-2023)
  • Table 121. Canada Kidney Disease, by Distribution Channel USD Million (2018-2023)
  • Table 122. Mexico Kidney Disease, by Type USD Million (2018-2023)
  • Table 123. Mexico Kidney Disease, by Treatment USD Million (2018-2023)
  • Table 124. Mexico Kidney Disease, by End-users USD Million (2018-2023)
  • Table 125. Mexico Kidney Disease, by Distribution Channel USD Million (2018-2023)
  • Table 126. Company Basic Information, Sales Area and Its Competitors
  • Table 127. Company Basic Information, Sales Area and Its Competitors
  • Table 128. Company Basic Information, Sales Area and Its Competitors
  • Table 129. Company Basic Information, Sales Area and Its Competitors
  • Table 130. Company Basic Information, Sales Area and Its Competitors
  • Table 131. Company Basic Information, Sales Area and Its Competitors
  • Table 132. Company Basic Information, Sales Area and Its Competitors
  • Table 133. Company Basic Information, Sales Area and Its Competitors
  • Table 134. Company Basic Information, Sales Area and Its Competitors
  • Table 135. Kidney Disease: by Type(USD Million)
  • Table 136. Kidney Disease Chronic Kidney Disease , by Region USD Million (2025-2030)
  • Table 137. Kidney Disease Acute Kidney Disease , by Region USD Million (2025-2030)
  • Table 138. Kidney Disease: by Treatment(USD Million)
  • Table 139. Kidney Disease Dialysis , by Region USD Million (2025-2030)
  • Table 140. Kidney Disease Medication , by Region USD Million (2025-2030)
  • Table 141. Kidney Disease Kidney Transplantation , by Region USD Million (2025-2030)
  • Table 142. Kidney Disease: by End-users(USD Million)
  • Table 143. Kidney Disease Dialysis Centers , by Region USD Million (2025-2030)
  • Table 144. Kidney Disease Hospital & Clinics , by Region USD Million (2025-2030)
  • Table 145. Kidney Disease Research and Academic Institutes , by Region USD Million (2025-2030)
  • Table 146. Kidney Disease: by Distribution Channel(USD Million)
  • Table 147. Kidney Disease Hospital Pharmacy , by Region USD Million (2025-2030)
  • Table 148. Kidney Disease Retail Pharmacy , by Region USD Million (2025-2030)
  • Table 149. Kidney Disease Online Pharmacy , by Region USD Million (2025-2030)
  • Table 150. Kidney Disease Others , by Region USD Million (2025-2030)
  • Table 151. South America Kidney Disease, by Country USD Million (2025-2030)
  • Table 152. South America Kidney Disease, by Type USD Million (2025-2030)
  • Table 153. South America Kidney Disease, by Treatment USD Million (2025-2030)
  • Table 154. South America Kidney Disease, by End-users USD Million (2025-2030)
  • Table 155. South America Kidney Disease, by Distribution Channel USD Million (2025-2030)
  • Table 156. Brazil Kidney Disease, by Type USD Million (2025-2030)
  • Table 157. Brazil Kidney Disease, by Treatment USD Million (2025-2030)
  • Table 158. Brazil Kidney Disease, by End-users USD Million (2025-2030)
  • Table 159. Brazil Kidney Disease, by Distribution Channel USD Million (2025-2030)
  • Table 160. Argentina Kidney Disease, by Type USD Million (2025-2030)
  • Table 161. Argentina Kidney Disease, by Treatment USD Million (2025-2030)
  • Table 162. Argentina Kidney Disease, by End-users USD Million (2025-2030)
  • Table 163. Argentina Kidney Disease, by Distribution Channel USD Million (2025-2030)
  • Table 164. Rest of South America Kidney Disease, by Type USD Million (2025-2030)
  • Table 165. Rest of South America Kidney Disease, by Treatment USD Million (2025-2030)
  • Table 166. Rest of South America Kidney Disease, by End-users USD Million (2025-2030)
  • Table 167. Rest of South America Kidney Disease, by Distribution Channel USD Million (2025-2030)
  • Table 168. Asia Pacific Kidney Disease, by Country USD Million (2025-2030)
  • Table 169. Asia Pacific Kidney Disease, by Type USD Million (2025-2030)
  • Table 170. Asia Pacific Kidney Disease, by Treatment USD Million (2025-2030)
  • Table 171. Asia Pacific Kidney Disease, by End-users USD Million (2025-2030)
  • Table 172. Asia Pacific Kidney Disease, by Distribution Channel USD Million (2025-2030)
  • Table 173. China Kidney Disease, by Type USD Million (2025-2030)
  • Table 174. China Kidney Disease, by Treatment USD Million (2025-2030)
  • Table 175. China Kidney Disease, by End-users USD Million (2025-2030)
  • Table 176. China Kidney Disease, by Distribution Channel USD Million (2025-2030)
  • Table 177. Japan Kidney Disease, by Type USD Million (2025-2030)
  • Table 178. Japan Kidney Disease, by Treatment USD Million (2025-2030)
  • Table 179. Japan Kidney Disease, by End-users USD Million (2025-2030)
  • Table 180. Japan Kidney Disease, by Distribution Channel USD Million (2025-2030)
  • Table 181. India Kidney Disease, by Type USD Million (2025-2030)
  • Table 182. India Kidney Disease, by Treatment USD Million (2025-2030)
  • Table 183. India Kidney Disease, by End-users USD Million (2025-2030)
  • Table 184. India Kidney Disease, by Distribution Channel USD Million (2025-2030)
  • Table 185. South Korea Kidney Disease, by Type USD Million (2025-2030)
  • Table 186. South Korea Kidney Disease, by Treatment USD Million (2025-2030)
  • Table 187. South Korea Kidney Disease, by End-users USD Million (2025-2030)
  • Table 188. South Korea Kidney Disease, by Distribution Channel USD Million (2025-2030)
  • Table 189. Taiwan Kidney Disease, by Type USD Million (2025-2030)
  • Table 190. Taiwan Kidney Disease, by Treatment USD Million (2025-2030)
  • Table 191. Taiwan Kidney Disease, by End-users USD Million (2025-2030)
  • Table 192. Taiwan Kidney Disease, by Distribution Channel USD Million (2025-2030)
  • Table 193. Australia Kidney Disease, by Type USD Million (2025-2030)
  • Table 194. Australia Kidney Disease, by Treatment USD Million (2025-2030)
  • Table 195. Australia Kidney Disease, by End-users USD Million (2025-2030)
  • Table 196. Australia Kidney Disease, by Distribution Channel USD Million (2025-2030)
  • Table 197. Rest of Asia-Pacific Kidney Disease, by Type USD Million (2025-2030)
  • Table 198. Rest of Asia-Pacific Kidney Disease, by Treatment USD Million (2025-2030)
  • Table 199. Rest of Asia-Pacific Kidney Disease, by End-users USD Million (2025-2030)
  • Table 200. Rest of Asia-Pacific Kidney Disease, by Distribution Channel USD Million (2025-2030)
  • Table 201. Europe Kidney Disease, by Country USD Million (2025-2030)
  • Table 202. Europe Kidney Disease, by Type USD Million (2025-2030)
  • Table 203. Europe Kidney Disease, by Treatment USD Million (2025-2030)
  • Table 204. Europe Kidney Disease, by End-users USD Million (2025-2030)
  • Table 205. Europe Kidney Disease, by Distribution Channel USD Million (2025-2030)
  • Table 206. Germany Kidney Disease, by Type USD Million (2025-2030)
  • Table 207. Germany Kidney Disease, by Treatment USD Million (2025-2030)
  • Table 208. Germany Kidney Disease, by End-users USD Million (2025-2030)
  • Table 209. Germany Kidney Disease, by Distribution Channel USD Million (2025-2030)
  • Table 210. France Kidney Disease, by Type USD Million (2025-2030)
  • Table 211. France Kidney Disease, by Treatment USD Million (2025-2030)
  • Table 212. France Kidney Disease, by End-users USD Million (2025-2030)
  • Table 213. France Kidney Disease, by Distribution Channel USD Million (2025-2030)
  • Table 214. Italy Kidney Disease, by Type USD Million (2025-2030)
  • Table 215. Italy Kidney Disease, by Treatment USD Million (2025-2030)
  • Table 216. Italy Kidney Disease, by End-users USD Million (2025-2030)
  • Table 217. Italy Kidney Disease, by Distribution Channel USD Million (2025-2030)
  • Table 218. United Kingdom Kidney Disease, by Type USD Million (2025-2030)
  • Table 219. United Kingdom Kidney Disease, by Treatment USD Million (2025-2030)
  • Table 220. United Kingdom Kidney Disease, by End-users USD Million (2025-2030)
  • Table 221. United Kingdom Kidney Disease, by Distribution Channel USD Million (2025-2030)
  • Table 222. Netherlands Kidney Disease, by Type USD Million (2025-2030)
  • Table 223. Netherlands Kidney Disease, by Treatment USD Million (2025-2030)
  • Table 224. Netherlands Kidney Disease, by End-users USD Million (2025-2030)
  • Table 225. Netherlands Kidney Disease, by Distribution Channel USD Million (2025-2030)
  • Table 226. Rest of Europe Kidney Disease, by Type USD Million (2025-2030)
  • Table 227. Rest of Europe Kidney Disease, by Treatment USD Million (2025-2030)
  • Table 228. Rest of Europe Kidney Disease, by End-users USD Million (2025-2030)
  • Table 229. Rest of Europe Kidney Disease, by Distribution Channel USD Million (2025-2030)
  • Table 230. MEA Kidney Disease, by Country USD Million (2025-2030)
  • Table 231. MEA Kidney Disease, by Type USD Million (2025-2030)
  • Table 232. MEA Kidney Disease, by Treatment USD Million (2025-2030)
  • Table 233. MEA Kidney Disease, by End-users USD Million (2025-2030)
  • Table 234. MEA Kidney Disease, by Distribution Channel USD Million (2025-2030)
  • Table 235. Middle East Kidney Disease, by Type USD Million (2025-2030)
  • Table 236. Middle East Kidney Disease, by Treatment USD Million (2025-2030)
  • Table 237. Middle East Kidney Disease, by End-users USD Million (2025-2030)
  • Table 238. Middle East Kidney Disease, by Distribution Channel USD Million (2025-2030)
  • Table 239. Africa Kidney Disease, by Type USD Million (2025-2030)
  • Table 240. Africa Kidney Disease, by Treatment USD Million (2025-2030)
  • Table 241. Africa Kidney Disease, by End-users USD Million (2025-2030)
  • Table 242. Africa Kidney Disease, by Distribution Channel USD Million (2025-2030)
  • Table 243. North America Kidney Disease, by Country USD Million (2025-2030)
  • Table 244. North America Kidney Disease, by Type USD Million (2025-2030)
  • Table 245. North America Kidney Disease, by Treatment USD Million (2025-2030)
  • Table 246. North America Kidney Disease, by End-users USD Million (2025-2030)
  • Table 247. North America Kidney Disease, by Distribution Channel USD Million (2025-2030)
  • Table 248. United States Kidney Disease, by Type USD Million (2025-2030)
  • Table 249. United States Kidney Disease, by Treatment USD Million (2025-2030)
  • Table 250. United States Kidney Disease, by End-users USD Million (2025-2030)
  • Table 251. United States Kidney Disease, by Distribution Channel USD Million (2025-2030)
  • Table 252. Canada Kidney Disease, by Type USD Million (2025-2030)
  • Table 253. Canada Kidney Disease, by Treatment USD Million (2025-2030)
  • Table 254. Canada Kidney Disease, by End-users USD Million (2025-2030)
  • Table 255. Canada Kidney Disease, by Distribution Channel USD Million (2025-2030)
  • Table 256. Mexico Kidney Disease, by Type USD Million (2025-2030)
  • Table 257. Mexico Kidney Disease, by Treatment USD Million (2025-2030)
  • Table 258. Mexico Kidney Disease, by End-users USD Million (2025-2030)
  • Table 259. Mexico Kidney Disease, by Distribution Channel USD Million (2025-2030)
  • Table 260. Research Programs/Design for This Report
  • Table 261. Key Data Information from Secondary Sources
  • Table 262. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Kidney Disease: by Type USD Million (2018-2023)
  • Figure 5. Global Kidney Disease: by Treatment USD Million (2018-2023)
  • Figure 6. Global Kidney Disease: by End-users USD Million (2018-2023)
  • Figure 7. Global Kidney Disease: by Distribution Channel USD Million (2018-2023)
  • Figure 8. South America Kidney Disease Share (%), by Country
  • Figure 9. Asia Pacific Kidney Disease Share (%), by Country
  • Figure 10. Europe Kidney Disease Share (%), by Country
  • Figure 11. MEA Kidney Disease Share (%), by Country
  • Figure 12. North America Kidney Disease Share (%), by Country
  • Figure 13. Global Kidney Disease share by Players 2023 (%)
  • Figure 14. Global Kidney Disease share by Players (Top 3) 2023(%)
  • Figure 15. Global Kidney Disease share by Players (Top 5) 2023(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. Taro Pharmaceutical Industries Ltd. (United States) Revenue, Net Income and Gross profit
  • Figure 18. Taro Pharmaceutical Industries Ltd. (United States) Revenue: by Geography 2023
  • Figure 19. Otsuka Pharmaceutical Co., Ltd. (Japan) Revenue, Net Income and Gross profit
  • Figure 20. Otsuka Pharmaceutical Co., Ltd. (Japan) Revenue: by Geography 2023
  • Figure 21. Novartis International AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 22. Novartis International AG (Switzerland) Revenue: by Geography 2023
  • Figure 23. Merck & Co. Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 24. Merck & Co. Inc. (United States) Revenue: by Geography 2023
  • Figure 25. Sanofi S.A. (France) Revenue, Net Income and Gross profit
  • Figure 26. Sanofi S.A. (France) Revenue: by Geography 2023
  • Figure 27. Amgen Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 28. Amgen Inc. (United States) Revenue: by Geography 2023
  • Figure 29. AstraZeneca plc (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 30. AstraZeneca plc (United Kingdom) Revenue: by Geography 2023
  • Figure 31. Teva Pharmaceutical Industries Ltd. (Israel) Revenue, Net Income and Gross profit
  • Figure 32. Teva Pharmaceutical Industries Ltd. (Israel) Revenue: by Geography 2023
  • Figure 33. Bristol-Myers Squibb Company (United States) Revenue, Net Income and Gross profit
  • Figure 34. Bristol-Myers Squibb Company (United States) Revenue: by Geography 2023
  • Figure 35. Global Kidney Disease: by Type USD Million (2025-2030)
  • Figure 36. Global Kidney Disease: by Treatment USD Million (2025-2030)
  • Figure 37. Global Kidney Disease: by End-users USD Million (2025-2030)
  • Figure 38. Global Kidney Disease: by Distribution Channel USD Million (2025-2030)
  • Figure 39. South America Kidney Disease Share (%), by Country
  • Figure 40. Asia Pacific Kidney Disease Share (%), by Country
  • Figure 41. Europe Kidney Disease Share (%), by Country
  • Figure 42. MEA Kidney Disease Share (%), by Country
  • Figure 43. North America Kidney Disease Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Taro Pharmaceutical Industries Ltd. (United States)
  • Otsuka Pharmaceutical Co., Ltd. (Japan)
  • Novartis International AG (Switzerland)
  • Merck & Co. Inc. (United States)
  • Sanofi S.A. (France)
  • Amgen Inc. (United States)
  • AstraZeneca plc (United Kingdom)
  • Teva Pharmaceutical Industries Ltd. (Israel)
  • Bristol-Myers Squibb Company (United States)
Additional players considered in the study are as follows:
Fresenius Kabi AG (Germany) , Pfizer Inc. (United States)
Select User Access Type

Key Highlights of Report


Jan 2024 215 Pages 63 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Kidney Disease Market Quantitative research analysis
Global Kidney Disease Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as Taro Pharmaceutical Industries Ltd. (United States), Otsuka Pharmaceutical Co., Ltd. (Japan), Novartis International AG (Switzerland), Merck & Co. Inc. (United States), Sanofi S.A. (France), Amgen Inc. (United States), AstraZeneca plc (United Kingdom), Teva Pharmaceutical Industries Ltd. (Israel) and Bristol-Myers Squibb Company (United States) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"Technological Advancements in Medical Science " is seen as one of major influencing trends for Kidney Disease Market during projected period 2023-2030.
The Kidney Disease market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Global Kidney Disease Market Report?

Have a Query? Click Here

Other Related Reports

Clonorchiasis Comprehensive Study by Treatment (Praziquantel, Cystic, Biltricide, Others), Parasites (Clonorchis Sinensis, Opisthorchis Viverrini, Opisthorchis Felineus, Others), Diagnosis (Microscop...
$ 3450
Carpal Tunnel Syndrome Comprehensive Study by Drugs (Ibuprofen, Prednisone, Triamcinolone, Others), Treatment (Bracing or Splinting, NSAIDs, Surgical Procedure, Others), End-users (Hospitals, Clinics...
$ 3750
Chapare Hemorrhagic Fever Comprehensive Study by Therapy (Antiviral, Electrolytes, Others), End-users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online...
$ 3350
Cercarial Dermatitis Comprehensive Study by Mode of Administration (Topical, Oral, Injectable), Distribution Channel (Online, Offline (Hospital Pharmacies, Retail Pharmacies, Dermatology Clinics)), D...
$ 3650
Capillaria Infection Comprehensive Study by Type (Intestinal Capillariasis, Hepatic Capillariasis), Drugs (Mebendazole, Albendazole, Steroids), End-users (Hospitals, Clinics, Others), Distribution Ch...
$ 3650
Candidiasis Comprehensive Study by Type (Candida Infections of the Mouth, Throat, and Esophagus, Vaginal Candidiasis, Invasive/Systemic Candidiasis), Route of Administration (Oral, Parenteral, Topica...
$ 3650